RecruitingPhase 2NCT06680830
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Studying Rapidly involuting congenital hemangioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Neuron23 Inc.
- Principal Investigator
- Fatta B Nahab, MD, FAAN FANANeuron23 Inc.
- Intervention
- NEU-411(drug)
- Enrollment
- 150 target
- Eligibility
- 40-80 years · All sexes
- Timeline
- 2025 – 2027
Study locations (30)
- Banner Sun Health Research Institute, Sun City, Arizona, United States
- University of Arkansas, Little Rock, Arkansas, United States
- Neuro-Pain Medical Center, Fresno, California, United States
- University of California, Irvine, Irvine, California, United States
- University of California, Los Angeles, Los Angeles, California, United States
- Esperanza Clinical, Murrieta, California, United States
- Parkinson's Research Centers of America - Palo Alto, Palo Alto, California, United States
- Sutter Neuroscience Institute, Sacramento, California, United States
- University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States
- Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
- University of Florida, Gainesville, Florida, United States
- Neurology One, Orlando, Florida, United States
- USF Parkinson's & Movement Disorders Clinic, Tampa, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Augusta University, Augusta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Qiagen Manchester Limited · Roche Diagnostic Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06680830 on ClinicalTrials.govOther trials for Rapidly involuting congenital hemangioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07415720Artichoke By-products Rich in Hydroxycinnamic Acids and Mediterranean Diet for Type 2 Diabetes Prevention.Clinica Universidad de Navarra, Universidad de Navarra
- RECRUITINGNANCT07532161Comparison Between Liquid Fibrin and Soft Laser Effects on Healing and Relapse After Lip Repositioning SurgeryDamascus University
- RECRUITINGNCT07558564Evaluation of Platelet-Rich Plasma (PRP) Treatment in TendinopathiesReSport Clinic
- RECRUITINGPHASE1, PHASE2NCT05991700Anthocyanin-Rich Table Grape Powder for Prophylaxis of Post-Operative Atrial FibrillationUniversity of Michigan
- RECRUITINGPHASE2NCT07466485The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD)Universiti Kebangsaan Malaysia Medical Centre
- RECRUITINGPHASE3NCT07448285Clinical Trial to Evaluate the Efficacy and Safety of Platelet-rich Plasma Infiltration in Chronic OmalgiaBiobizkaia Health Research Institute
- RECRUITINGPHASE2NCT07470359Comparison of Functional Outcomes Following Arthroscopic ACL Reconstruction With Peroneus Longus Autograft With and Without Intra-articular Platelet-Rich Plasma Injection.Lahore General Hospital
- RECRUITINGNANCT07004777Effect of Consuming n-3 PUFAs Rich Foods on Triglyceride Concentration and Lipoprotein CompositionInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
See all trials for Rapidly involuting congenital hemangioma →